[6-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]吡啶-3-基]甲醇 | 331746-72-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: [6-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]吡啶-3-基]甲醇
• 英文名称: {6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}methanol
• 英文别名: {6-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-3-yl}-methanol；{6-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-3-pyridyl}-methanol；[6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl]methanol
• CAS: 331746-72-6
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: ZGQOKHSXRIFEDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  68.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [6-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]吡啶-3-基]甲醇 在 草酰氯 、 sodium hexamethyldisilazane 、 sodium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 10.0h， 生成 ethyl 2-ethoxy-3-{6-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]pyridin-3-yl}propanoate
  参考文献：
  名称：

  Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

  摘要：

  A series of novel pyridine-3-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compounds (S)-14 and (S)-19 were selected for further profiling.

  DOI：

  10.1016/j.bmcl.2006.08.110
• 作为产物：
  描述：

  2-(5-甲基-2-苯基-1,3-恶唑-4-基)-1-乙醇 在 sodium tetrahydroborate 、 正丁基锂 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 为溶剂， 反应 18.0h， 生成 [6-[2-(5-甲基-2-苯基-1,3-恶唑-4-基)乙氧基]吡啶-3-基]甲醇
  参考文献：
  名称：

  Pyridine-3-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

  摘要：

  A series of novel pyridine-3-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARalpha/gamma agonists with varied isoform selectivity. Based on the results of efficacy studies in diabetic (db/db) mice, and the desired pharmacokinetic parameters, compounds (S)-14 and (S)-19 were selected for further profiling.

  DOI：

  10.1016/j.bmcl.2006.08.110

文献信息

• Antidiabetic agents
  申请人：——

  公开号：US20030171377A1

  公开（公告）日：2003-09-11

  The present invention provides compounds of Formula (I): 1 wherein A, X, Q, Y, B, D, Z, and E have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates useful for preparing compounds of Formula I.

  本发明提供了式(I)的化合物： 1 其中A、X、Q、Y、B、D、Z和E具有规范中定义的任何值，以及药用可接受的盐，这些化合物作为抗糖尿病药是有用的。还公开了包含一个或多个式I化合物的药物组合物，制备式I化合物的方法，以及用于制备式I化合物的中间体。
• Alpha substituted carboxylic acids
  申请人：Su Guo Wei

  公开号：US20050187266A1

  公开（公告）日：2005-08-25

  Alpha substituted carboxylic acids of formula (I): wherein R 1 and R 2 are as defined in the specification and R 3 is wherein Y, Ar 1 , Ar 2 , Ar 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 9a , R 10 , R 11 , R 12 , R 17 , ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

  式(I)的α取代羧酸，其中R1和R2如规范中定义，R3为，其中Y、Ar1、Ar2、Ar3、R4、R5、R6、R7、R8、R9、R9a、R10、R11、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/γ相关疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。
• [EN] ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS<br/>[FR] ACIDES CARBOXYLIQUES ALPHA-SUBSTITUES COMME MODULATEURS DU RECEPTEUR ACTIVE PAR LES PROLIFERATEURS DE PEROXYSOME (PPAR)
  申请人：PFIZER

  公开号：WO2004092145A1

  公开（公告）日：2004-10-28

  Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R', R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

  式(I)的α-取代羧酸，其中R'和R2如规范中定义，R3为A)式(II)；B)式(III)；C)式(IV)；和D)式(V)；其中Y、Art、Are、AP、R4、R5、R6、R7、R6、R9、R9a、R10、R'、R12、R17、环A和p如规范中定义；含有所述化合物或其盐的有效量的药物组合物对于治疗PPAR，特别是PPAR α/y相关的疾病，如糖尿病、血脂异常、肥胖和炎症性疾病是有用的。
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：Cheng T. Peter

  公开号：US20070015797A1

  公开（公告）日：2007-01-18

  Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R 1 , R 2 , R 2a , R 2b , R 2c , R 3 , Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供了一些化合物，它们的结构如下：其中Q为C或N，A为O或S，Z为O或键，X为CH或N，R1、R2、R2a、R2b、R2c、R3、Y、x、m和n如此定义，这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
• Oral antidiabetic agents
  申请人：Warner-Lambert Company LLC

  公开号：EP1577305A1

  公开（公告）日：2005-09-21

  The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein:    A is    X is CH2-CH2-O or -CH2CH2CH2-;    Q is    Y is CH2;    Z is absent;    B is H;    D is H, and E is CO2H; that are useful as antidiabetic agents. Also disclosed are pharmaceutical compositions comprising compounds of formula (I).

  本发明提供了式 (I) 的化合物 或其药学上可接受的盐，其中 A 是 X是CH2-CH2-O或-CH2CH2CH2-； Q 是 Y 是 CH2 Z 不存在； B 是 H； D 是 H、 和 E 是 CO2H； 可用作抗糖尿病药物。还公开了包含式（I）化合物的药物组合物。